For physicians: CA-62 in clinical practice
What the test shows, how to interpret the result, publications and reference tools.
How the test worksFour diagrams: source of the marker, repeat testing, difference from conventional markers, the scale.
Reference toolsInteractive CA-62 result reference: reference interval, CRP context and repeat-testing intervals recommended by the manufacturer.
Publications17 items since 2019: articles, conference posters, preprints, patents, with PDFs.
Clinical significance
- What it measures
- Membrane proteins with a distinctive N-glycosylation pattern typical of poorly differentiated cells. The level reflects proliferative and metabolic activity of the tumour, not its mass; elevated levels have been described with tumours from 5 mm.
- Place in diagnostics
- A non-organ-specific signal of accumulating poorly differentiated cells, including when the location of the process is not yet known. Conventional markers work within organ-specific diagnostics: clarification, monitoring, assessment of confirmed disease. The methods complement each other, as do molecular tests.
- Accuracy
- 89–94% sensitivity at stage I–II with 95% specificity (blinded studies at Sechenov University, 489 patients and 141 healthy participants). Sensitivity declines only slightly at later stages.
- Spectrum
- Accuracy is statistically confirmed for carcinomas of the breast, prostate, lung, ovary, kidney and colorectum. Detection cases are described for most tumours, including choroidal melanoma. Sarcomas are not detected; low-Ki-67 tumours are detected later.
- Interpretation
- Reference interval: up to and including 5,000 U/mL. Above the interval, the manufacturer recommends repeat testing in 30–60 days; with CRP < 10 mg/L the work-up may start without waiting for the repeat. An isolated elevation is not a diagnosis.
- Scale
- Competitive assay: luminescence in the order of 10⁶ at ~1,000 U/mL and hundreds above 7,000 U/mL; 4,500 and 5,500 U/mL differ in signal by about two orders of magnitude. Close values are not compared directly.
- Levels
- In patients with suspected cancer, a large share of tumours show levels above 7,000 U/mL. In a prospective study of patients with CT-suspected lung cancer, 87.5% of early cases were above 5,000 U/mL (92.5% versus apparently healthy controls); early adenocarcinomas are more often up to 7,000, squamous cell carcinomas above 7,000.
- Above cut-off in healthy people
- Among apparently healthy people — about 3% under 40, 5% at 45–60, 6% over 55.
- Inflammation
- The marker responds to stem cell division during the immune response, not to cytokines. Chronic inflammatory diseases in remission — elevation in no more than 5% of cases; autoimmune diseases — up to 50% (psoriasis — isolated cases).
- Use
- Primary detection and annual check-ups, screening programmes, monitoring during and after treatment.
- Regulatory status
- Laboratory-developed test (LDT) in North America since 2025. Roszdravnadzor registration certificate No. RZN 2020/9880 of 3 April 2020 — the world’s first multi-cancer (MCED) test system for detecting epithelial carcinomas with no restriction on tumour site to be authorised for use by a government authority.
Publications and patents
Articles, conference posters, preprints and patents on CA-62, newest first. Posters and patents are available as PDFs.
| Date | Type | Publication | Summary | Links |
|---|---|---|---|---|
| Aug 2026 | Poster | CA-62 and Combined Biomarker Performance in Pulmonary Lesions: Prospective Confirmation Next Generation Dx Summit 2026 | Prospective study at Botkin Hospital, Moscow (May 2025 – April 2026): 267 patients with CT-detected lung lesions and biopsy. CA-62 was above 5,000 U/mL in 85.4% of primary lung cancers and in 87.2% at stage I–II (41 of 47); CEA and CYFRA 21-1 were raised in only 23.4% and 12.8% of early cases. | |
| May 2026 | Preprint | Using CA-62 Marker in a Pilot Screening Project in Kazakhstan, 2021: Baseline Data and Scenario-Based Modeling of Estimated Specificity Preprints.org | Baseline data from a pilot screening of 1,214 asymptomatic healthcare workers in Kazakhstan: 7.5% of results above 5,000 U/mL, modelled specificity 92.8–94.8%. Not peer-reviewed. | Preprints.org · PDF |
| Aug 2025 | Poster | Balancing High NPV and Insufficient PPV: Results of a Pilot Cancer Screening Study Using the CA-62 Biomarker, with Applicability to its Commercial Use Next Generation Dx Summit 2025 | Pilot screening of 1,005 employees over 45 with occupational cancer risk: 6.2% of results above 5,000 U/mL. CA-62 flagged all 10 known but untreated cancers; one more stage I endometrial cancer was found within a year. PPV 17.5%; no cancer emerged among the 942 people with a normal result. | |
| May 2025 | Article | Diagnostic significance of the novel biomarker combination for early-stage non-small cell lung cancer detection: results of the blind clinical study Frontiers in Oncology, 2025, 15 | Double-blind study of 304 people (141 with NSCLC, 133 healthy, 30 with COPD): CA-62 sensitivity at stage I–II 92% at 95% specificity, AUC 0.973. | Publisher page |
| Aug 2024 | Poster | The Challenge of Early-stage Cancer Detection Next Generation Dx Summit 2024 | Why early cancer is hard to detect at low prevalence, and how a repeat test raises PPV. Screening of 1,000 employees over 50: NPV 100%, PPV 15.9%; model of PPV gain from a repeat CA-62 after 30–60 days. | |
| Jun 2024 | Conference abstract | CA-62: A new biomarker for the detection of early-stage renal cell carcinoma ASCO Annual Meeting 2024, J Clin Oncol 42 (16 suppl), abstr. 4526 | 204 people (68 with early-stage kidney cancer, 136 healthy): CA-62 sensitivity 94.3% at 96% specificity. | Publisher page · PDF |
| May 2024 | Patent | Novel cancer antigen for early cancer detection, methods for its production, isolation and detection Patent RU 2818471 C2, priority 22 Apr 2020, published 2 May 2024 | The CA-62 cancer antigen, a family of 60–85 kDa N-glycoproteins with identical N-glycosylation, and the method for its detection. Patent holder: JVS Diagnostics LLC. | FIPS register · PDF |
| Aug 2023 | Poster | CA-62: A Novel Screening Biomarker for Early Cancer Detection 15th Next Generation Dx Summit, Washington DC, 2023 | Double-blind study: 600 samples from patients with breast, prostate, lung, kidney and colorectal cancer and 200 controls. CA-62 sensitivity at stage I–II 86–94% at 97% specificity. | |
| Jun 2023 | Article | Practical application of the CA-62 tumor marker in the initial diagnosis of oncological disease of epithelial origin: assistance to the doctor in interpreting the results Consilium Medicum, 2023, 25 (6): 406–414 | Review of blinded clinical studies of CA-62 in breast, prostate, colorectal cancer and NSCLC; guidance for physicians on interpreting results. | Publisher page |
| Jun 2023 | Conference abstract | A novel three-biomarker signature (CA-62, CEA, CYFRA 21-1) and early-stage NSC lung cancer detection ASCO Annual Meeting 2023, J Clin Oncol 41 (16 suppl), abstr. 3038 | 304 samples: the combination of CA-62, CEA and CYFRA 21-1 detected early NSCLC with 93% sensitivity at 100% specificity. | Publisher page |
| May 2023 | Article | Clinical validation of the novel CLIA-CA-62 assay efficacy for early-stage breast cancer detection Frontiers in Oncology, 2023, 13: 1009863 | Blinded study of 196 patients (mostly DCIS and stage I–II) and 73 healthy women. CA-62 detected 92% of cancers at 93% specificity, including 100% of DCIS and 97% of stage I. | Publisher page |
| May 2023 | Article | Diagnostic significance of CA-62 cancer antigen for early detection and differential diagnosis of non-small cell lung cancer: results of the blind clinical trials Современная онкология / Journal of Modern Oncology, 2023, 25 (1): 82–90 | Double-blind study, 304 samples: CA-62 separated NSCLC from controls better than CEA, CYFRA 21-1 and SCC (AUC 0.981), with about 92% sensitivity at stage I–II. | Publisher page |
| 2023 | Article | Potential clinical application of the cancer antigen CA-62 for differential diagnosis of prostate cancer and benign prostatic hyperplasia at the elevated prostate-specific antigen Research and Practical Medicine Journal, 2023, 10 (1): 10–26 | Blinded study of 325 men: CA-62 helps distinguish prostate cancer from benign hyperplasia in the PSA “grey zone” of 2.5–10 ng/mL. | Publisher page |
| 2022 | Poster | Logistic Regression Using a Combination of CA-62, CA 15-3, and Age for Detecting Early Stages of Breast Cancer in Screening ISOBM Congress 2022, Slovenia | Logistic regression on CA-62, CA 15-3 and age in 300 breast cancer patients and 141 healthy women: 93.3% sensitivity at 99.3% specificity, AUC 0.988, versus 75% with simple combined cut-offs. | |
| 2022 | Article | Diagnostic efficacy of the new prospective biomarker’s combination CA 15-3 and CA-62 for early-stage breast cancer detection: Results of the blind prospective-retrospective clinical study Cancer Biomarkers, 2022, 35 (1): 57–69 | Blinded study, 488 samples: the CA 15-3 and CA-62 combination detected 75% of DCIS and stage I breast cancer at 100% specificity. | Publisher page |
| Nov 2020 | Patent | Reagent kit for detecting a marker of epithelial carcinomas Patent RU 2735918 C2, priority 7 Jun 2018, published 10 Nov 2020 | Reagent kit for measuring CA-62 in serum, the basis of the registered test system. Patent holder: JVS Diagnostics LLC. | FIPS register · PDF |
| 2019 | Article | A pilot clinical trial to monitor response to chemotherapy using the CA-62 marker of epithelial carcinomas Siberian Journal of Oncology, 2019, 18 (5): 18–28 | Monthly CA-62 monitoring in 89 patients during chemotherapy: marker dynamics matched RECIST response in about 84% of cases. | Publisher page |
Reference tools
Interactive CA-62 result reference: where the result sits relative to the reference interval and the repeat-testing interval recommended by the manufacturer.
Questions to the developers and clinical discussion — in the Telegram chat for physicians t.me/EarlyDiagnosisPractice. Partnerships with clinics and requests for materials: info@oncomarker.ru.